Nano-X Imaging (NNOX) Is Up 46.8% After Boosting 2026 Outlook and Expanding AI Imaging Partnerships

• Earlier this week, Nano-X Imaging Ltd. announced a 2026 revenue outlook of US$35 million, alongside expanded commercial partnerships, including a reseller agreement with 3DR Labs and deployments in France, after unveiling its FDA-cleared Nanox.ARC X digital tomosynthesis system at RSNA 2025.
• This series of developments positions Nano-X Imaging for accelerated international growth and wider adoption of its AI-enhanced imaging solutions within major healthcare networks.
• Now, we'll explore how Nano-X Imaging's upbeat 2026 revenue guidance and enhanced AI partnerships may impact its investment narrative.

The latest GPUs need a type of rare earth metal called Neodymium and there are only 36 companies in the world exploring or producing it. Find the list for free.

Nano-X Imaging Investment Narrative Recap

For those considering Nano-X Imaging, the core belief centers on its potential to disrupt medical imaging through affordable tomosynthesis systems and AI-powered diagnostics at scale. This week’s upbeat 2026 revenue outlook and major new commercial deals, including expanded partnerships in Europe and the United States, provide a boost to near-term market confidence. However, these developments do not fully resolve the biggest immediate risk: continued unprofitability and slow utilization of installed imaging units, which remain barriers to transformative revenue growth and profitability.

Among the recent updates, the partnership with 3DR Labs stands out by giving Nano-X Imaging’s FDA-cleared AI solutions access to more than 1,800 healthcare sites across North America. This move directly ties into the company’s most visible catalyst: accelerating active deployments, which could help shift revenue mix from teleradiology services to innovative hardware and software for long-term gains. Still, as commercial rollouts increase, investors should pay close attention to...

Read the full narrative on Nano-X Imaging (it's free!)

Nano-X Imaging's outlook suggests $72.6 million in revenue and $3.9 million in earnings by 2028. This scenario assumes an 82.8% annual revenue growth rate and a $59.6 million increase in earnings from the current level of -$55.7 million.

Uncover how Nano-X Imaging's forecasts yield a $7.75 fair value, a 78% upside to its current price.

Exploring Other Perspectives

Simply Wall St Community users provide 5 fair value estimates for Nano-X Imaging, ranging from US$0.87 to US$10 per share. While expectations for rapid revenue growth persist, major execution risks could shape very different outcomes, see how others price the opportunity.

Explore 5 other fair value estimates on Nano-X Imaging - why the stock might be worth less than half the current price!

Build Your Own Nano-X Imaging Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Nano-X Imaging research is our analysis highlighting 1 key reward and 2 important warning signs that could impact your investment decision.
• Our free Nano-X Imaging research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Nano-X Imaging's overall financial health at a glance.

Want Some Alternatives?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• Find companies with promising cash flow potential yet trading below their fair value.
• AI is about to change healthcare. These 30 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Uncover the next big thing with financially sound penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com